Donepezil Hydrochloride
Product Images NDC 63187-401
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63187-401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig 2 (0002)
Fig 3 (0003)
The text describes a chart or graph that shows the percentage of patients who have taken either Donepezil Hydrochloride 10mg/day or 5mg/day or a placebo. Below the chart, there is a rating system called CIBIC-plus, which rates the improvement of the patients from markedly improved to minimally improved or worse.*
Fig 4 (0004)
This appears to be a chart / graph of a clinical study evaluating the effect of Donepezil Hydrochloride on clinical improvement and decline over several weeks of drug treatment compared to placebo. There are two different dosage options given (10mg/day and 5mg/day) and the chart shows that patients on Donepezil Hydrochloride experienced a higher level of clinical improvement compared to placebo, as well as a slower rate of decline.*
Fig 5 (0005)
This appears to be a clinical research data table showing the change in ADAS-cog for different treatments groups. The treatments include Donepezil, Hydrochloride 10 mg/day, Hydrochloride 5 mg/day, and a placebo. The table also includes the cumulative percentage of patients for each treatment group.*
Fig 6 (0006)
Fig 7 (0007)
The text seems to be a table showing the mean change from baseline for SIB (Severe Impairment Battery) score after 3 to 6 months of drug treatment in a clinical trial. The first column indicates the treatment group (Donepezil Hydrochloride 10 mg/day or Placebo), while the second column shows the mean change in SIB score. The third row mentions "Clinical Decline".*
Fig 8 (0008)
Fig 9 (0009)
Fig 10 (0010)
The text describes a medication called Donepezil Hydrochloride that is taken at a dosage of 10 milligrams per day. There is a comparison to a placebo indicated on a chart with varying percentages. The text references an "ADCS-ADL Change from Baseline" score, but no further information is provided to clarify the meaning of the score.*
Fig 11 (0011)
Fig 12 (0012)
Fig 13 (0013)
This text appears to be a medication prescription for Donepezil Hydrochloride with two different doses mentioned: 23 mg/day and 10 mg/day. The remaining text seems to be a chart indicating the status of the medication's effect on the patient, ranging from improvement to worsening. Therefore, it may be a medical document related to the dosage and performance of Donepezil Hydrochloride.*
Donepezil Hydrochloride (Donepezil Hydrochloride)
Donepezil 10mg (Donepezil Hydrocloride 5 mg)
This is a description of Donepezil HCI 10mg tablets with NDC 63187-401-30. The tablets are white to off-white, round, film-coated and are debossed with “J” on one side and “10" on the other side. The product ID is RD040130, and they are manufactured by Jubilant Life Sciences Limited in Roorkee-247661, India. The tablets are available in a pack of 30 with lot #: 00000 Exp: 00/00/00. The medication should be stored at 20°-25°C (68°-77°F) and out of the reach of children. The product has been relabeled by Proficient Rx LP located in Thousand Oaks, CA 91320.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.